|
|
Article: Novartis gets broader FDA indication, for heart failure, on Diovan.
- Article from:
- Pharma Marketletter
- Article date:
- August 15, 2005
CopyrightCOPYRIGHT 2005 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The US Food and Drug Administration has approved Swiss pharmaceutical major Novartis' Diovan (valsartan), the most-prescribed angiotensin receptor blocker worldwide, for a new indication - that of reducing cardiovascular death in patients at high risk (with left ventricular failure or left ventricular dysfunction) following a heart attack.
The FDA has also expanded the drug's heart-failure labeling, so that Diovan can now be prescribed in a broader range of heart failure patients and is no longer limited to those intolerant of angiotensin-converting enzyme inhibitors.
Novartis notes that Diovan is now the only agent in its class across the world ...